Astrazeneca Pharma India Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

July 3, 2026
Posted by: Kunal Singla
Category: News

Astrazeneca Pharma India CMP Rs.8,239. Market cap Rs.20,590 Cr. PE 109.8. 12-month target Rs.8,321-9,392.

Astrazeneca Pharma India Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Astrazeneca Pharma India shares trading at Rs.8,239 against a market capitalisation of Rs.20,590 Cr and a price-to-earnings multiple of 109.8. As a pharmaceuticals and life sciences name on the NSE and BSE, Astrazeneca Pharma India enters the Astrazeneca Pharma India Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

Quarterly financials for Astrazeneca Pharma India are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE/BSE filings directly for the Astrazeneca Pharma India Q1 Results FY27 result date and cross-check any figures before making investment decisions.

Get Free Investment Predictions and Astrazeneca Pharma India Research at Univest

Astrazeneca Pharma India (NSE: ASTRAZEN) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings ahead of the Astrazeneca Pharma India Q1 Results FY27 season, forming the base against which the Astrazeneca Pharma India Q1 Results FY27 estimates in this article are built. This Astrazeneca Pharma India Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Table of Contents

Astrazeneca Pharma India Q1 FY27 Estimates

Metric	Detail
CMP	Rs.8,239
Market Cap	Rs.20,590 Cr
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.8,321-9,392

Univest, a SEBI-Registered Investment Advisor, Tracks Astrazeneca Pharma India Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. CDMO Pipeline Visibility

Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Astrazeneca Pharma India’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Astrazeneca Pharma India share price target or faces renewed pressure.

2. New Product Approvals

New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Astrazeneca Pharma India’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Astrazeneca Pharma India share price target or faces renewed pressure.

3. Capacity Scale-Up

Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Astrazeneca Pharma India’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Astrazeneca Pharma India share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Astrazeneca Pharma India’s live price and Q1 FY27 result updates.

Key Risks to the Astrazeneca Pharma India Q1 Results FY27 Outlook

Pricing pressure in key export markets, particularly the US generics segment.
Regulatory or plant compliance issues affecting supply continuity.
R&D and capacity expansion costs weighing on near-term profitability.

Q4 FY26 Performance Context

Detailed Q4 FY26 financials for Astrazeneca Pharma India were not available from Univest’s data partners at the time of writing. Investors should check Screener.in or the company’s exchange filings for the latest verified numbers before the Q1 FY27 results.

Technical Analysis Ahead of Astrazeneca Pharma India Q1 Results FY27

Astrazeneca Pharma India shares last traded at Rs.8,239. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Astrazeneca Pharma India Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Astrazeneca Pharma India Q1 Results FY27 trailing-growth framework points to a range of Rs.8,082-8,742 for Astrazeneca Pharma India, contingent on the Astrazeneca Pharma India Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Astrazeneca Pharma India Q1 Results FY27 view for Astrazeneca Pharma India works out to Rs.8,321-9,392, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Astrazeneca Pharma India Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Astrazeneca Pharma India Q1 Results FY27 analysis would put Astrazeneca Pharma India in a Rs.8,783-10,266 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Astrazeneca Pharma India Q1 Results FY27 Print

Revenue and PAT versus the Astrazeneca Pharma India Q1 Results FY27 estimate range in this preview.
Management commentary on FY27 growth guidance and margin trajectory relevant to the Astrazeneca Pharma India Q1 Results FY27 narrative.
Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
Pricing pressure in key export markets, particularly the US generics segment

Conclusion on Astrazeneca Pharma India Q1 Results FY27

Astrazeneca Pharma India enters the Q1 FY27 results season trading at Rs.8,239, with the 12-month Uniresearch target range of Rs.8,321-9,392 reflecting a tracking stance. Investors tracking the Astrazeneca Pharma India Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Astrazeneca Pharma India Q1 Results FY27

When are Astrazeneca Pharma India Q1 FY27 results expected?

Ans. Astrazeneca Pharma India’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Astrazeneca Pharma India Q1 FY27 revenue estimate?

Ans. Detailed quarterly estimates are not available for Astrazeneca Pharma India at this time; check Screener.in or the company’s exchange filings for verified numbers.

What is the Astrazeneca Pharma India share price target?

Ans. The 12-month Uniresearch estimate for Astrazeneca Pharma India share price target is Rs.8,321-9,392, based on trailing growth and current valuation multiples.

Is Astrazeneca Pharma India a good buy before Q1 FY27 results?

Ans. Astrazeneca Pharma India is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Astrazeneca Pharma India’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.

Where can I track Astrazeneca Pharma India share price live?

Ans. Astrazeneca Pharma India share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.